首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Effectiveness of an Indian-made Attenuated influenza A(H1N1)pdm 2009 vaccine
【2h】

Effectiveness of an Indian-made Attenuated influenza A(H1N1)pdm 2009 vaccine

机译:印度制造的2009年减毒A(H1N1)pdm减毒流感疫苗的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A live attenuated influenza A(H1N1)pdm 2009 vaccine was developed and distributed in India in 2010. We estimated the vaccine effectiveness (VE) against laboratory-confirmed pandemic H1N1 (pH1N1) infections in patients with influenza-like illness who visited five tertiary care hospitals in Pune, India during June–December 2010. Swab specimens were analyzed for influenza pH1N1 by reverse transcriptase polymerase chain reaction (RT-PCR). VE was estimated using the test-negative case-control study design and logistic regression. A total of 784 patients (253 cases, 531 controls) were analyzed. The unadjusted overall VE was 75.5% (95% confidence interval [CI] 42.1–89.7), while the adjusted VE was 76% (95% CI 42.1–89.7). We conclude that the live attenuated influenza A(H1N1)pdm 2009 vaccine was effective in our study population, which has opened prospects for using this platform for trivalent formulations.
机译:于2009年开发了一种减毒活2009年A(H1N1)pdm活疫苗,并在印度分发。我们估计了对接受过五次三级护理的类流感患者经实验室确认的大流行H1N1(pH1N1)感染的疫苗有效性(VE) 2010年6月至12月,在印度浦那的一家医院中进行了研究。采用逆转录聚合酶链反应(RT-PCR)分析了拭子标本中的pH1N1流感。使用测试阴性的病例对照研究设计和logistic回归估算VE。总共分析了784例患者(253例,531例对照)。未经调整的整体VE为75.5%(95%置信区间[CI] 42.1-89.7),而经过调整的VE为76%(95%CI 42.1-89.7)。我们得出的结论是,2009年减毒活流感A(H1N1)pdm疫苗在我们的研究人群中有效,这为将该平台用于三价制剂开辟了前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号